<DOC>
	<DOC>NCT02836873</DOC>
	<brief_summary>The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and moderate renal impairment.</brief_summary>
	<brief_title>Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment</brief_title>
	<detailed_description>Approximately 52 investigative site globally are planned to participate in this study. An estimated 300 subjects with poorly controlled T2DM and moderate renal impairment will be randomly assigned to receive bexagliflozin tablets, 20 mg, or placebo in equal ratio for 24 weeks.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>1. Males or females with T2DM with inadequate glycemic control 2. Diagnosis of moderate renal impairment 4) Body Mass Index â‰¤ 45 kg/m2 1. Diagnosis of type 1 diabetes mellitus or maturityonset/diabetes of the young 2. Women who are pregnant or nursing 3. Subjects who are receiving renal replacement therapy or have undergone renal transplantation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>